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Background: Pontocerebellar hypoplasia (PCH) represents a group of neurodegenerative disorders with prenatal
onset. Eight subtypes have been described thus far (PCH1-8) based on clinical and genetic features. Common
characteristics include hypoplasia and atrophy of the cerebellum, variable pontine atrophy, and severe mental and
motor impairments. PCH1 is distinctly characterized by the combination with degeneration of spinal motor
neurons. Recently, mutations in the exosome component 3 gene (EXOSC3) have been identified in approximately
half of the patients with PCH subtype 1.
Methods: We selected a cohort of 99 PCH patients (90 families) tested negative for mutations in the TSEN genes,
RARS2, VRK1 and CASK. Patients in this cohort were referred with a tentative diagnose PCH type 1, 2, 4, 7 or
unclassified PCH. Genetic analysis of the EXOSC3 gene was performed using Sanger sequencing. Clinical data, MR
images and autopsy reports of patients positive for EXOSC3 mutations were analyzed.
Results: EXOSC3 mutations were found in twelve families with PCH subtype 1, and were not found in patients with
other PCH subtypes. Identified mutations included a large deletion, nonsense and missense mutations. Examination
of clinical data reveals a prolonged disease course in patients with a homozygous p.D132A mutation. MRI shows
variable pontine hypoplasia in EXOSC3 mediated PCH, where the pons is largely preserved in patients with a
homozygous p.D132A mutation, but attenuated in patients with other mutations. Additionally, bilateral cerebellar
cysts were found in patients compound heterozygous for a p.D132A mutation and a nonsense allele.
Conclusions: EXOSC3 mediated PCH shows clear genotype-phenotype correlations. A homozygous p.D132A
mutation leads to PCH with possible survival into early puberty, and preservation of the pons. Compound
heterozygosity for a p.D132A mutation and a nonsense or p.Y109N allele, a homozygous p.G31A mutation or a p.G135E
mutation causes a more rapidly progressive course leading to death in infancy and attenuation of the ventral pons.
Our findings imply a clear correlation between genetic mutation and clinical outcome in EXOSC3 mediated PCH,
including variable involvement of the pons.
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Pontocerebellar hypoplasias represent a group of autosomal
recessive neurodegenerative disorders with prenatal onset.
Patients of all subtypes show variable hypoplasia/atrophy
of pons and cerebellum and severe motor and cognitive
impairments. Based on clinical and genetic criteria, eight
subtypes of PCH have been classified (PCH1-8). PCH1
(MIM607596, 614678) is a distinctive subtype of PCH,
and is characterized by degeneration of motor neurons in
the anterior spinal horn, morphologically similar to spinal
muscular atrophy (SMA). PCH1 patients present a broad
phenotypic spectrum, ranging from neonatal death [1] to
survival into puberty ([2] and patients 7-I and 7-II in this
paper). In few families diagnosed with PCH1, mutations
have been found in TSEN54 [3], RARS2 [4] and vaccinia-
related kinase 1 (VRK1) [5]. Approximately half of PCH1
families carry mutations in EXOSC3, the gene encoding
exosome component 3 [2,6-9].
In this study, we report EXOSC3 mutations in twelve
families with PCH1. We categorised the patients according
to genetic mutation, and correlate this with clinical severity
and size of the ventral pons.
Methods
Patient cohort
Our laboratory is a reference centre for PCH genetic ana-
lysis. We received EDTA-blood or DNA samples from
hospitals and institutes worldwide for genetic analysis of
genes associated with PCH. For this study, we selected
DNA material from a cohort of 99 patients (90 families)
diagnosed by referring specialists with PCH type 1, 2, 4, 7 or
an unknown PCH-like anomaly. All cases were negative for
mutations in genes known to cause PCH (TSEN54,TSEN34,
TSEN2, RARS2, VRK1 and CASK). Informed consent was
obtained by referring specialists.
Genetic analysis
PCR primer pairs for EXOSC3 [NM_016042.2] were
designed for all exons including intron-exon boundar-
ies using Primer3 software (http://frodo.wi.mit.edu/).
For primer sequences, see Additional file 1. Sanger se-
quencing of PCR amplified DNA was performed using
BigDyeTerminator chemistry (Applied Biosystems) and
analysed on an ABI3730xl sequencer. Sequences were ana-
lysed using CodonCode Aligner software 3.6.1. Analysis of
gene mutations was done with the Alamut software
package (Interactive Biosoftware, version 2.0), which in-
cludes the splice site prediction algorithms SpliceSiteFinder,
MaxEntScan and Human Splicing Finder. Detection of
large deletions in EXOSC3 was initially performed with
you-MAQ assay (Multiplicon), using primers in the
5’UTR and intron 3 (see Additional file 1). Detailed
analysis of the deletion in patient 8 was performed
with the SequalPrep Long PCR Kit (Life Technologies),using primers in the 3’UTR and upstream of EXOSC3
(see Additional file 1).
Neuroimaging
Routine MR images of EXOSC3 mutation positive patients
were re-examined. Coronal cerebellar images from pa-
tients found to be positive for mutations in EXOSC3
were subclassified as previously described [4]. The main
impact of the process that causes pontine hypoplasia/
atrophy is on the ventral pons, which leaves the dorsal
area (tegmentum) relatively unaffected [10,11]. The ventral
pons and tegmentum can be distinguished on routine MRI.
On midsagittal MR scans, surfaces of these areas were
determined using ITK-SNAP 2.4.0 software [12] and ventral
pons/(ventral pons+tegmentum) (VP/(VP+T)) ratios were
determined as a measure for pontine hypoplasia/atrophy.
Three-dimensional images were constructed based on a
series of MR scans using the same software. The control
group consists of MR images obtained from children
(n=23; neonatal to 11y) referred by paediatric neurolo-
gists for diagnostic MRI, whose brain MR image was
considered normal.
Histological stainings
Paraffinised sections of the pons were stained with
Luxol/PAS following standard protocols as described
previously [13].
Results
EXOSC3 molecular analysis
Screening of a cohort of 99 patients (90 families) with
various PCH subtypes revealed EXOSC3 mutations in
fourteen PCH patients (twelve families, Table 1). Six
patients were homozygous for the c. 92G>C (p.G31A)
mutation, three patients were homozygous for the
c.395A>C (p.D132A) mutation, and one patient was homo-
zygous for the c.404G>A (p.G135E) mutation. We found
four patients to be compound heterozygous for EXOSC3
mutations (patients 8, 9, 10 and 11). Patient 8 had a
hemizygous p.D132A mutation and a heterozygous 6,171
nucleotide large deletion containing the promoter region,
the first three exons and a part of intron 3 of the EXOSC3
gene (g.del37781240-37787410), without affecting adjacent
genes. Patient 9 had a heterozygous p.D132A mutation
and a c.743_749delinsA mutation, leading to a premature
stop codon (p.L248*). Patient 10 had a p.D132A mutation
on the maternal allele. On the paternal allele, this patient
had a c.334G>A (p.V112I) variation in addition to a nine
nucleotide duplication leading to a premature stop codon
(c.325-4_329dupGTAGTATGT; p.P111*). The p.V112I
amino acid change was predicted to be benign by SIFT
(score 0,32) and Align GVGD (class C0), and possibly
damaging by PolyPhen-2 (score 0,949). Patient 11 had the
p.D132A mutation plus a c.325T>A (p.Y109N) mutation.
Table 1 Clinical data of 14 patients with EXOSC3 mutation
1 2 3 4 5-I 5-II 6 7-I
Nucleotide change c.92G > C c.92G > C c.92G > C c.92G > C c.92G > C c.92G > C c.395A > C c.395A > C
Amino acid change p.G31A p.G31A p.G31A p.G31A p.G31A p.G31A p.D132A p.D132A
Ethnic background Roma Roma Roma Roma Roma Roma Caucasian Caucasian
Pregnancy duration 39w, CS at term 38w 37w 37w 40w 39w u
Hypotonia at birth + + + + + + + +
OFC (SD)a (age) −4 (1.5 m) −2.5 (birth) 0 (birth) +3 (4.5mo) 0 (4mo) +2.5 (4mo) +3 (4.5mo) −0.5 (11y)
Nystagmus - - u + - - + +
Optic atrophy Pale optic disc - u - - - - u
Seizures - - - - - - - +
Dyskinesia/dystonia - - - - - - + 1 episode, admitted
with high temp and
pneunomia
+
Tendon reflexes absent absent absent absent absent absent brisk brisk
Response on visual/
auditory stimuli
- - u - - - ++ +
Age at death (cause) 4.5mo (cardiac arrest) 7mo (pneumonia, sepsis) 5d (respiratory failure) 5mo (u) 6mo (viral infection) 4mo (u) 7y (respiratory failure) 12y (GI failure)
Lower motor neuron signs Neurogenic
muscle atrophy
Neurogenic
muscle atrophy
u, diagnosed
following patient
5-II (cousin)
Tongue fasciculations,
denervation (EMG),
neurogenic muscle
atrophy
u, diagnosed
following patient
5-II (sister)
Muscle
denervation
(EMG)
u u, diagnosed
following patient
7-II (brother)
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Table 1 Clinical data of 14 patients with EXOSC3 mutation (Continued)
7-II 8 9 10 11 12
Nucleotide change c.395A > C c.395A > C (he)
g.del37781240-37787410 (he)
c.395A > C (he)
c.743_749delinsA (he)
c.325-4_329dupGTAGTATGT
(he) c.334G > A (he)
c.395A > C (he)
c.325 T > A (he)
c.395A > C (he)
c.404G > A
Amino acid change p.D132A p.D132A; deletion exon 1-3 p.D132A; p.L248* p.P111*; p.V112I; p.D132A p.Y109N; p.D132A p.G135E
Ethnic background Caucasian Caucasian Caucasian Caucasian Caucasian Pakistan
Pregnancy duration 35w 39w 38w 42w 41w 40w
Hypotonia at birth + + + ± + +
OFC (SD)a (age) −2 (6.5y) −1 (birth) u −0.5 (10w) −1.5 (6.5mo) −1 (8w)
Nystagmus + - u - - +
Optic atrophy u + u - Small optic discs Pale optic disc
Seizures - + West syndrome at 5 mo - - - -
Dyskinesia/dystonia + - - - - -
Tendon reflexes reduced reduced absent reduced absent absent
Response on visual/
auditory stimuli
+ ± - ± - -
Age at death (cause) 10y (pseudomonas infection) 6mo (respiratory infection) 14w (respiratory failure) 6mo (respiratory infection) 8.5mo
(respiratory failure)
8w (respiratory failure)
Lower motor neuron signs Denervation (EMG) Neurogenic muscle atrophy Denervation (EMG) Denervation (EMG),
reduced motor nerve
conduction velocity
Tongue fasciculations,
neurogenic muscle
atrophy
Denervation,
neurogenic
muscle atrophy
he = heterozygous; d = days; w = weeks; mo =months; y = years; u = unknown; ++ =markedly present; + = present; ± =mildly present; - = not present.
aSD for head circumference according to WHO standards (http://www.who.int/childgrowth/standards/hc_for_age/en/index.html).
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the mutation is not predicted to affect splicing by the
SpliceSiteFinder, MaxEntScan and Human Splicing Finder
software. Unfortunately, tissue was not available for splicing
studies. The p.Y109N missense mutation was predicted to
be deleterious by PolyPhen-2 (score 1,000), SIFT (score 0,0)
and Align-GVGD (class C65). In all cases, we confirmed
the mutations by sequencing the parents. In case of ex-
pected compound heterozygosity, we could show that
the mutations were on different alleles.
In our cohort with different PCH subtypes, all twelve
families harbouring EXOSC3 mutations were diagnosed
as PCH1. In four other PCH1 families in our cohort we
could not detect mutations in coding regions of this gene.
No EXOSC3 mutations were found in patients diagnosed
with other types of PCH. Therefore, EXOSC3 mutations
seem to be exclusively associated with the PCH1 subtype.
The patients harbouring the p.G31A mutation are all
of Romani descent - although living in different coun-
tries (Sweden and Hungary) - suggesting a common
founder as proposed earlier [7,9]. The families with the
p.D132A allele are all of Caucasian descent.
Clinical data of patients with EXOSC3 mutations
Most EXOSC3 mutation positive patients were previously
diagnosed as PCH1 based on clinical features. Although
patients 3 and 5-I were not tested for lower motor neuron
symptoms, they were diagnosed following the diagnosis of
patient 5-II, which is patient 5-IIs sister and patient 3s
cousin. Interestingly, patients 6, 7-I and 7-II were initially
not diagnosed as PCH1, as it was yet unknown that the
PCH1 spectrum was broad, and that patients could survive
childhood [6]. The finding of depleted motor neurons on
autopsy in these patients confirmed PCH1 diagnosis.
Clinical features of EXOSC3 positive patients in our
cohort are summarized in Table 1. Based on genetic
mutations, our cohort can be divided in four subgroups: 1.
homozygosity for the p.G31A mutation; 2. homozygosity
for the p.D132A mutation; 3. compound heterozygosity
for the p.D132A mutation on one allele and a deletion,
nonsense or missense mutation on the other allele;
4. homozygosity for the p.G135E mutation.
In the p.G31A group (six patients, five families),
hypotonic pareses were present at birth in five patients,
and observed at one month in one patient. No patients
were born with polyhydramnios, though all suffered from
swallowing insufficiency. Tendon reflexes and responses to
external stimuli were absent in all patients in this group. At
birth, severe contractures were present in two patients: pa-
tient 2 presented with contractures in the knee joints and
had equinovarus foot deformities; patient 4 had contrac-
tures in hips, ankles, elbows, hands and fingers. Dyskinesia
or seizures were not observed in this group. Mild facial
dysmorphisms were observed in three of the six patients,including low set ears (2/6), broad nasal bridge (2/6)
and short palpebral fissures (2/6). Two patients had
microcephaly (patient 1: -4 SD at 1.5 months of age;
patient 2: -2.5SD at birth), while others had normal or
even large OFCs (patient 4: +3SD at 4.5 months of age) at
the time of presentation. All homozygous p.G31A patients
died during infancy (median age of death 4.75 months,
range 5 days to 7 months).
In the p.D132A group (three patients, two families),
hypotonia was found at birth in two patients, and at 13
weeks in one patient. No polyhydramnios was observed in
this group. Tendon reflexes were either brisk (2/3 patients)
or reduced (1/3 patients). Patients in this group were able
to respond to visual and auditory stimuli. For example,
patient 6 recognized familiar faces and voices, made
social eye contact and babbled at the age of six years.
Patients 7-I and 7-II had remarkably good cognitive
skills compared to other PCH patients - the boys were
able to move a computer mouse to make simple ‘yes’ or
‘no’ choices in a computer game. Due to severe motor im-
pairments adequate testing of IQ was not possible, but
parents and caretakers considered these brothers’ intellec-
tual skills age appropriate. Swallowing insufficiency was
present in all three patients. Severe contractures at birth
were not seen in this group. From the age of 5 and 4 years
respectively, patients 7-I and 7-II developed progressively
internally rotated arms and weak, claw-like deformity
of the hands. Dyskinesia was reported sporadically in
patient 6 and regularly in patients 7-I and 7-II. Patient
7-I had initially few generalised seizures per year, which
increased in frequency and severity until death. This
patient also developed intense visceral pains and ultim-
ately succumbed to his gastrointestinal tract malfunction-
ing. All three patients in this group survived into childhood
(age of death 7, 12 and 10 years respectively).
The third group consists of patients with a p.D132A
mutation in combination with a null allele or missense
mutation in the EXOSC3 gene (four patients, four families).
All patients were hypotonic at birth, with multiple contrac-
tures in three patients. Two patients could be breastfed or
bottle fed in the first weeks of life, but developed swallow-
ing difficulties later on. Tendon reflexes were absent (2/4)
or reduced (2/4). Dyskinesia was not reported in this group.
Seizures are reported in two patients: patient 8 developed
West Syndrome at the age of 5 months and in patient 10
seizures were reported by his parents in the days before his
death. Facial dysmorphisms in two patients included
low set ears and large soft ear helices. In addition, patient
10 presented fat distribution as seen in CDG1a, and patient
11 had a small penis and hypoplastic scrotum. The patients
died during infancy (median age of death 6 months, range
3.5 to 8.5 months).
One patient in our cohort was homozygous for the p.
G135E (c.404G>A) mutation. Born from consanguineous
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he was hypotonic and had contractures of elbows and
knees. He had nystagmus, pale optic discs and failed to
respond to external stimuli. The patient died at the age
of 8 weeks.
Brain imaging studies
MR images of the brain were available for all patients,
except for patient 1. Based on coronal images, we cate-
gorised the cerebellar hemisphere patterns as described
previously [4]: a dragonfly type (flattened hemispheres,
relative prominence of vermis), a butterfly type (small
but normally proportioned cerebellum) and a postnatal
atrophy-like type (cerebellar atrophy rather than hypoplasia
with the hemispheres reaching the margins of the posterior
fossa in at least one spot). As a measure for pontine
hypoplasia/atrophy we determined the VP/(VP+T) ratio on
midsagittal MR images (Figure 1A).
In the p.G31A group, four of the five cerebellar
hemisphere pathologies resembled a dragonfly pattern
(Figure 2A). Patient 5-I presented a butterfly-like cere-
bellar pattern, albeit hemispheres are smaller than aA B
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Figure 1 Ventral pons/tegmentum ratios in PCH patients. On midsagit
defined as shown in Figure A. Patients with a homozygous p.D132A mutat
controls (n=23, age neonatal to 11y). Patients with a homozygous p.G31A
(n=4) or a homozygous p.G135E mutation (n=1) show a decreased ratio, ap
TSEN54 gene (n=6) (B). Three-dimensional images were constructed of the
an attenuated pons in a patient 5-I (C, homozygous p.G31A mutation) and
homozygous p.D132A) or a control subject (F). Scale bar in C-F=1cm. VP=vtypical butterfly pattern. In the p.G31A group, the
pons is significantly attenuated compared to controls
(p<0.01; Figure 1B, C). Supratentorial abnormalities are
seen in three of the five patients in this group: these
patients had widened extracerebral CSF spaces, and one
patient (patient 4, born at 37 weeks gestational age) pre-
sented delayed neocortical maturation.
All three patients with a homozygous p.D132A muta-
tion showed a postnatal atrophy-like cerebellar pattern
(Figure 2B). Patient 6 showed supratentorial abnormalities:
she had enlarged ventricles due to atrophy of the basal
ganglia. Patient 7-II underwent a CT scan at the age of
one year, which was normal. An MRI performed at the
age of five years showed a small cerebellum, suggesting
progressive atrophy. The VP/(VP+T) ratio in this group
equals that of healthy controls (Figure 1B, F), indicating
a largely unaffected pons in patients with a p.D132A
mutation (Figure 1B, D).
Three of the four patients in the compound heterozygous
group presented a dragonfly cerebellum. One patient in this
group (patient 9) presented a butterfly pattern. Cerebellar
cysts were common in this group (3/4 patients) (Figure 2C)..D132A + deletion 
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tal MR images, surfaces of ventral pons and pontine tegmentum were
ion in EXOSC3 (n=3) present a pons/tegmentum ratio comparable to
mutation (n=5), a p.D132A mutation plus a nonsense or p.Y109N allele
proaching that seen in patients with a p.A307S mutation in the
pons, tegmentum and part of the medulla. The reconstructions show
patient 8 (E, p.D132A plus large deletion) compared to patient 7-I (D,
entral pons; T=tegmentum.
A B C
Figure 2 Brain MRI of PCH patients with an EXOSC3 mutation. Sagittal and coronal images of a patient with a homozygous p.G31A mutation
(A, patient 5-II, age 2w), a patient with a homozygous p.D132A mutation (B, patient 7-I, age 11y) and a patient with a p.D132A mutation and large
deletion (C, patient 8, age 1mo). Cerebellar cysts in this last patient are indicated by arrow heads.
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(mild atrophy of the cerebral hemispheres and caudate
nuclei and widened ventricles) and patient 11 (thin corpus
callosum). Midsagittal pons measurements showed pontine
attenuation in this group (Figure 1B, E).
The patient homozygous for the p.G135E mutation
presents with cerebellar cysts and no supratentorial
abnormalities. Since no coronal image was available
for this patient, it is hard to describe the pattern type
of the cerebellar hemispheres. Ratio of midsagittal pons/
tegmentum surface in this patient is comparable to the
p.G31A group (Figure 1B).
To conclude, the genotype-phenotype correlation of
the various EXOSC3 mutations is reflected in the severity
of cerebellar and pontine hypoplasia.
Neuropathological findings
Autopsy was performed on one patient with a p.G31A
mutation (patient 1). No MRI was made of this patient,
but post mortem results showed atrophy of cerebellar
hemispheres, inferior and middle cerebellar peduncles.
The cerebellar hemispheres were poorly developed and
presented a smooth surface. Histological analysis showed
a reduced number of Purkinje cells and a fragmented
dentate nucleus. The number of transverse pontine fibres
and pontine neurons was reduced compared to control
tissue (Figure 3).
Post mortem studies were performed on all three patients
with a p.D132A mutation. In all, atrophy of cerebellar
hemispheres and vermis was noted, including a reduced
number of Purkinje cells. Characteristic for PCH1 – thenumber of motor neurons in the anterior spinal horn was
reduced. Residual motor neurons showed a shrunken and
angulated morphology. In one patient (7-I), depletion of
neurons in the dorsal horn was also seen. Examination of
the pons revealed proportionate reduction of transverse
pontine fibres, descending fibres and pontine nuclei in
patient 6. No pontine abnormalities were found in pa-
tient 7-I and 7-II, in line with the normal appearance
of the pons on MRI. Cerebral anomalies were found
in patients 7-I and 7-II: both presented neuron loss,
gliosis and calcifications in the thalamus.
Discussion
We performed genetic screening on 99 subjects with
various types of PCH. Among this cohort, we identified
fourteen PCH1 patients (twelve families) with mutations
in EXOSC3, suggesting that mutations in this gene are
restricted to PCH subtype 1. Four families with PCH1
that we screened for EXOSC3 mutations did not have
mutations in coding regions of this gene. In addition to
the EXOSC3 mutations described previously, we identified
five novel variants in EXOSC3, leading to an amino acid
substitution or a nonsense allele.
After the identification of EXOSC3 as a PCH associated
gene [6], many different mutations have been found in this
gene (Table 2). This genetic heterogeneity is reflected in the
broad phenotypic spectrum of EXOSC3 mediated PCH,
ranging from relatively mild (e.g. compound heterozygous
p.D132A/p.V80F mutation [2]) to severe (e.g. homozygous
p.G31A mutation [9]). Findings by us and others [6-8],
show that EXOSC3 mutations underlie about half of the
DC
A
VP
T
B
VP
T
p.G31Acontrol
Figure 3 Pons abnormalities in patient with p.G31A mutation. Luxol/PAS staining of the pons shows small pons and reduction of transverse
pontine fibres (B) and pontine neurons (D) in a patient with a homozygous p.G31A mutation (patient 1) compared to age matched control
(A and C). Scale bar A and B=0.5cm, C and D=100μm. VP=ventral pons; T=tegmentum.
Eggens et al. Orphanet Journal of Rare Diseases 2014, 9:23 Page 8 of 10
http://www.ojrd.com/content/9/1/23PCH1 cases. EXOSC3 mediated PCH shows a genotype-
phenotype correlation: the p.D132A mutation leads to a
relatively prolonged disease course including survival into
childhood, limited social interaction and preservation of
the pons. A homozygous p.G31A mutation, or a p.D132A
in combination with a nonsense or p.Y109N mutation
leads to a more severe type of PCH reflected in clinical
symptoms, death during infancy and hypoplasia of theTable 2 Overview of mutations identified in EXOSC3
Allele A Allele B
p.G31A (c.92G > C) p.G31A (c.92G > C)
p.G31A (c.92G > C) p.W238R (c.712 T > C)
p.D132A (c.395A > C) p.D132A (c.395A > C)
p.D132A (c.395A > C) start codon affected (c.2 T >
p.D132A (c.395A > C) p.P52Rfs*2 (c.155delC)
p.D132A (c.395A > C) p.D76Gfs*49 (c.226dupG)
p.D132A (c.395A > C) p.V80F (c.238G > T)
p.D132A (c.395A > C) p.V99Wfs*11 (c.294_303del)
p.D132A (c.395A > C) p.Y109N (c.325 T > A)
p.D132A (c.395A > C) p.P111*; p.V112I (c.325-4_329
p.D132A (c.395A > C) p.A139P (c.415G > C)
p.D132A (c.395A > C) exon 3 skipping (c.475-12A >
p.D132A (c.395A > C) p.C184Lfs*19 (c.551delG)
p.D132A (c.395A > C) p.L248* (c.743_749delinsA)
p.D132A (c.395A > C) deletion exon 1–3 (g.del3778
p.G135E (c.404G > A) p.G135E (c.404G > A)pons. The patient with a homozygous p.G135E mutation
shows a similarly severe phenotype.
Previous research suggested that patients with an
EXOSC3 mutation show a relatively preserved pons in
comparison to other types of PCH [4,7,8]. We have quan-
tified this and we demonstrate that the pons/tegmentum
ratio on midsagittal MR images of patients with a
homozygous p.D132A mutation indeed resembles thatReference
[6,7,9] This paper
[6,7]
[6-8] This paper
C) [7]
[7]
[7]
[2]
[6]
This paper
dupGTAGTATGT; c. 334G > A) This paper
[6]
G) [6,7]
[7]
This paper
1240-37787410) This paper
This paper
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tions in EXOSC3, the pons/tegmentum ratio was decreased.
The ratio in patients with a homozygous p.G31A muta-
tion does not differ significantly from PCH patients with
a p.A307S mutation in the TSEN54 gene, although we
should keep in mind that the cohorts are small (p.G31A
five patients; p.A307S six patients). Interestingly, our con-
trol group shows that the ventral pons/tegmentum ratio is
rather stable over a large age range (0 to 11 years). MRI
analysis showed the presence of cerebellar cysts in 4/
14 patients with mutations in EXOSC3. Intracerebellar
cysts have been reported before in few severe cases of
PCH1 [3,14]. Their morphology closely resembles cysts
in PCH2 [4]. Our results support the occurrence of
cysts in severe PCH1.
Due to motor handicaps intellectual performance
could not be studied in detail, but behavioral study suggests
normal cognition in some patients in the p.D132A group
([2], patients 7-I and 7-II in this paper).
The visceral pain of which patient 7-I suffered from,
is a phenomenon not previously reported in PCH1.
Neuropathological post-mortem examination of this pa-
tient revealed degeneration of neurons in both the ventral
and dorsal spinal horn. Degeneration of neurons in the
dorsal horn may account for the chronic visceral pains in
this patient. Patient 7-II had a normal CT brain scan at 1
year of age, but cerebellar hypoplasia on MRI at 5 years of
age, demonstrating the progressive nature of the disease.
Additionally, it emphasizes the importance of serial brain
imaging in diagnosing PCH.
Motor disorders such as dyskinesia and spasticity were
only observed in the p.D132A group which is charactarised
by prolonged survival.
To conclude, we show that within the broad spectrum
of EXOSC3 mediated PCH, clear genotype-phenotype cor-
relations can be made. A homozygous p.D132A mutation
leads to a more chronic form of PCH, with survival into
childhood, and preservation of the pons. Compound
heterozygosity for a p.D132A mutation and a nonsense
or p.Y109N allele, a homozygous p.G31A mutation or a
p.G135E mutation causes a severe disease course including
death during infancy and hypoplasia of the pons.
Conclusions
We identified new nonsense and missense mutations in
the EXOSC3 gene and we show that mutations in this gene
are exclusively found in PCH1 patients. There are evident
genotype-phenotype correlations in EXOSC3-mediated
PCH reflected in clinical outcome, age of death and pons
hypoplasia: patients with a homozygous p.D132A mutation
have a prolonged disease course compared to patients with
a p.D132A allele plus a nonsense or p.Y109N mutation.
Patients with a homozygous p.G31A mutation and the
patient with a homozygous p.G135E mutation presenta similarly severe phenotype with death in infancy. Our
results refine the current view of an unaffected pons in
EXOSC3 mediated PCH.
Additional file
Additional file 1: Supplementary methods.
Abbreviations
PCH: Pontocerebellar hypoplasia; SMA: Spinal muscular atrophy;
PCR: Polymerase chain reaction; MR(I): Magnetic resonance (imaging);
VP: Ventral pons; T: Tegmentum.
Competing interests
The authors declare to have no competing interests.
Authors’ contribution
VRCE collected and analysed the data and wrote the manuscript. PGB had a
valuable contribution in writing and revising the manuscript. FvR, MBD-dW
and MTvM performed molecular genetic analysis. PGB, JFN and BTP-T
analysed MRI scans and were closely involved in discussions. JNB, ND, AD, JF,
NF, DF, TH, TJ, MK, PM, AM, JARN, DO’R, SP, ANW, LW, MS and LS provided
clinical information. EA, DT, TJ and TH provided post mortem tissue and
stainings. CBM and HAM were involved in neuroradiological analysis. FB
coordinated the study and the writing of the manuscript. All authors read,
revised and approved the final manuscript.
Author details
1Department of Genome Analysis, Academic Medical Centre, Amsterdam, the
Netherlands. 2Division of Pediatric Neurology, Emma’s Children’s Hospital,
Academic Medical Centre, Amsterdam, the Netherlands. 3Division of
Pathology and Neuroscience, University of Dundee, Dundee, UK.
4Department of Paediatrics, University of Gothenburg, The Queen Silvia’s
Children Hospital, Gothenburg, Sweden. 5Clinical Genetics, Nottingham City
Hospital, Nottingham, UK. 6Pediatric Neurology, Children’s Hospital, Geneva,
Switzerland. 7Clinical Genetics Service, Southampton University Hospitals
Trust, Southampton, UK. 8Paediatric Pathology, University Hospital
Southampton NHS Trust, Southampton, UK. 9Department of Neuropathology,
Institute of Pathology, University of Debrecen, Debrecen, Hungary. 10Neural
Development Unit, UCL Institute of Child Health and the Department of
Histopathology, Great Ormond Street Hospital for Children NHS Foundation
Trust, London, UK. 11Paediatric Neurology, Childrens University Hospital,
Temple St., Dublin, Ireland. 12Department of Genetic Medicine and
Development, University of Geneva, Geneva, Switzerland. 13Department of
Neurosurgery, University of Szeged, Szeged, Hungary. 14Clinical and
Experimental Sciences, University of Southampton, Southampton, UK.
15Virtual Academic Unit, Child Development Centre, Northampton, Northants,
UK. 16Clinical Genetics, Great Ormond Street Hospital, London, UK.
17Department of Paediatrics, University of Szeged, Szeged, Hungary.
18Department of (Neuro)Pathology, Academic Center, University of the
Netherlands, Amsterdam, the Netherlands. 19Department of Radiology,
Academic Medical Center, Amsterdam, the Netherlands. 20Department of
Biomedical Engineering and Physics, AMC, Amsterdam, the Netherlands.
Received: 31 October 2013 Accepted: 6 February 2014
Published: 13 February 2014
References
1. Barth PG: Pontocerebellar hypoplasias. An overview of a group of
inherited neurodegenerative disorders with fetal onset. Brain Dev 1993,
15:411–422.
2. Zanni G, Scotton C, Passarelli C, Fang M, Barresi S, Dallapiccola B, et al:
Exome sequencing in a family with intellectual disability, early onset
spasticity, and cerebellar atrophy detects a novel mutation in EXOSC3.
Neurogenetics 2013, 14:247–250.
3. Simonati A, Cassandrini D, Bazan D, Santorelli FM: TSEN54 mutation in a
child with pontocerebellar hypoplasia type 1. Acta Neuropathol 2011,
121:671–673.
Eggens et al. Orphanet Journal of Rare Diseases 2014, 9:23 Page 10 of 10
http://www.ojrd.com/content/9/1/234. Namavar Y, Barth PG, Kasher PR, van RF, Brockmann K, Bernert G, et al:
Clinical, neuroradiological and genetic findings in pontocerebellar
hypoplasia. Brain 2011, 134:143–156.
5. Renbaum P, Kellerman E, Jaron R, Geiger D, Segel R, Lee M, et al: Spinal
muscular atrophy with pontocerebellar hypoplasia is caused by a
mutation in the VRK1 gene. Am J Hum Genet 2009, 85:281–289.
6. Wan J, Yourshaw M, Mamsa H, Rudnik-Schoneborn S, Menezes MP, Hong JE,
et al: Mutations in the RNA exosome component gene EXOSC3 cause
pontocerebellar hypoplasia and spinal motor neuron degeneration.
Nat Genet 2012, 44:704–708.
7. Rudnik-Schoneborn S, Senderek J, Jen JC, Houge G, Seeman P, Puchmajerova
A, et al: Pontocerebellar hypoplasia type 1: clinical spectrum and relevance
of EXOSC3 mutations. Neurology 2013, 80:438–446.
8. Biancheri R, Cassandrini D, Pinto F, Trovato R, Di RM, Mirabelli-Badenier M,
et al: EXOSC3 mutations in isolated cerebellar hypoplasia and spinal
anterior horn involvement. J Neurol 2013, 260:1866–1870.
9. Schwabova J, Brozkova DS, Petrak B, Mojzisova M, Pavlickova K, Haberlova J,
et al: Homozygous EXOSC3 mutation c.92G–>C, p.G31A is a founder
mutation causing severe Pontocerebellar Hypoplasia Type 1 among the
Czech Roma. J Neurogenet 2013, 27:163–169.
10. Barth PG, Blennow G, Lenard HG, Begeer JH, van der Kley JM, Hanefeld F,
et al: The syndrome of autosomal recessive pontocerebellar hypoplasia,
microcephaly, and extrapyramidal dyskinesia (pontocerebellar
hypoplasia type 2): compiled data from 10 pedigrees. Neurology 1995,
45:311–317.
11. Goutieres F, Aicardi J, Farkas E: Anterior horn cell disease associated with
pontocerebellar hypoplasia in infants. J Neurol Neurosurg Psychiatry 1977,
40:370–378.
12. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al: User-guided
3D active contour segmentation of anatomical structures: significantly
improved efficiency and reliability. Neuroimage 2006, 31:1116–1128.
13. Goto N: Discriminative staining methods for the nervous system: luxol
fast blue–periodic acid-Schiff–hematoxylin triple stain and subsidiary
staining methods. Stain Technol 1987, 62:305–315.
14. de Leon GA, Grover WD, D'Cruz CA: Amyotrophic cerebellar hypoplasia:
a specific form of infantile spinal atrophy. Acta Neuropathol 1984, 63:282–286.
doi:10.1186/1750-1172-9-23
Cite this article as: Eggens et al.: EXOSC3 mutations in pontocerebellar
hypoplasia type 1: novel mutations and genotype-phenotype correlations.
Orphanet Journal of Rare Diseases 2014 9:23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
